Stockreport

AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction

AVITA MEDICAL  (AVMXY) 
NASDAQ:AMEX Investor Relations: avitamedical.com/investors
PDF First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months VAL [Read more]